Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq: FHTX) has announced its participation in two virtual investor conferences. The first is the Morgan Stanley Virtual Annual Global Healthcare Conference on September 9, 2021, featuring a fireside chat and one-on-one meetings. The second is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, with a presentation and one-on-one meetings. Presentations will be available on-demand, and replays can be accessed for 90 days. Foghorn focuses on developing medicines that target the chromatin regulatory system in oncology.

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn management will participate in two upcoming virtual investor conferences.

Events:

Morgan Stanley Virtual Annual Global Healthcare Conference
Format: Fireside Chat and investor 1x1 meetings
Thursday, September 9, 2021
11:45am ET
Please find a link to the presentation here. A replay will be available for 90 days.

H.C. Wainwright 23^rd Annual Global Investment Conference
Format: Presentation and investor 1x1 meetings
Monday, September 13, 2021
All company presentations will be available on-demand beginning at 7:00am ET
Please find a link to the presentation here.

A webcast of both presentations can also be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com

About Foghorn Therapeutics

Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology.

Media Contact:

Fanny Cavalié, Foghorn Therapeutics Inc.
fcavalie@foghorntx.com 

Gregory Kelley, Ogilvy
gregory.kelley@ogilvy.com 

Investor Relations Contact:

Ben Strain, Foghorn Therapeutics Inc.
bstrain@foghorntx.com 

Hans Vitzthum, LifeSci Advisors
617-430-7578
hans@lifesciadvisors.com 

FAQ

When is Foghorn Therapeutics participating in the Morgan Stanley Virtual Annual Global Healthcare Conference?

Foghorn Therapeutics will participate in the Morgan Stanley Virtual Annual Global Healthcare Conference on September 9, 2021.

What is the format of the Morgan Stanley Virtual Annual Global Healthcare Conference for FHTX?

The format includes a fireside chat and investor one-on-one meetings.

When will Foghorn Therapeutics present at the H.C. Wainwright 23rd Annual Global Investment Conference?

Foghorn Therapeutics will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

How long will the Foghorn presentations be available for replay?

The presentations will be available for replay for 90 days.

What is the main focus of Foghorn Therapeutics as a company?

Foghorn Therapeutics focuses on discovering and developing medicines that target genetically determined dependencies within the chromatin regulatory system, particularly in oncology.